Novel agents in development for peripheral T-cell lymphoma.

Owen A O'Connor

Journal: Seminars in hematology 2010;47 Suppl 1():S11-4

PMID: 20359580

Full Text on Elsevier Science View on PubMed

Abstract

Though peripheral T-cell lymphoma (PTCL) is an area of significant unmet therapeutic need, a number of new treatment options are available for patients, especially those with relapsed or refractory disease. A plethora of drugs are now in development for PTCL, but drugs that truly target novel disease biology are noticeably absent. Combinations of T-cell centric agents could produce novel platforms of therapy to replace the relatively ineffective CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-based regimens. Among agents with T-cell activity are the folate analog pralatrexate, histone deacetylase inhibitors (HDACi) like romidepsin, the proteasome inhibitor bortezomib, the immunomodulatory agent lenalidomide, the purine nucleoside phosphorylase (PNP) inhibitor forodesine, the nucleoside analog gemcitabine, and BH3-only mimetics like ABT-263 and ABT-737.

Address: New York University Cancer Institute, NYU Langone Medical Center, New York, NY, USA. O'[email protected]

DOI: 10.1053/j.seminhematol.2010.01.014

Link outs

Free resources

Miscellaneous:

https://assays.cancer.gov/CPTAC-570

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-DDIT3-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Aminopterin, Antimetabolites, Antineoplastic, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Bortezomib, Clinical Trials as Topic, Depsipeptides, Drug Design, Drugs, Investigational, Histone Deacetylase Inhibitors, Humans, Immunologic Factors, Lenalidomide, Lymphoma, T-Cell, Peripheral, Purine Nucleosides, Pyrazines, Pyrimidinones, Salvage Therapy, Thalidomide